Compare Mesoblast Limited (MESO) vs Prudential Financial Inc (PRU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Prudential Financial Inc — how do they compare? Mesoblast Limited trades at $14.29 (market cap $1.75B), while Prudential Financial Inc trades at $113.09 (market cap $39.17B). The key difference: Prudential Financial Inc is far larger — about 22.4× Mesoblast Limited's market cap, and Prudential Financial Inc pays a 4.93% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 15 Days and Prudential Financial Inc for 145 Days on average.
| MESO | PRU | |
|---|---|---|
Market Cap | $1.75B | $39.17B |
Volume | 239,027 | 1,436,917 |
Sector | Health | Financials |
52-Week High | $20.96 | $125.13 |
52-Week Low | $13.19 | $92.00 |
Typical Hold Time | 15 Days | 145 Days |
Enterprise Value | $1.83B | $67.95B |
Dividend Yield | — | 4.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $14.29, up 2.51% today, amid bearish technical signals but positive fundamental developments. The stock shows strong revenue growth with FY2026 reaching $120 million, though profitability remains negative. Recent FDA approval for Ryoncil's potency assay and completion of Phase 3 back pain trials provide catalysts. Technical indicators show oversold conditions with RSI at 22.4, while moving averages signal bearish momentum.
Investment outlook balances high growth potential against persistent losses. The expanding Ryoncil market share and pipeline progress offer upside, but negative margins and cash burn pose risks. Analyst consensus leans bullish with 45% buy ratings, yet the stock faces execution challenges in achieving profitability amid competitive pressures.
Prudential Financial (PRU) trades at $113.53, up 1.04% with a bearish technical signal despite recent earnings beats. The stock shows attractive valuation metrics with P/E of 10.29 and P/S of 0.61, while maintaining solid profitability with 6.04% net margin and 12.46% ROE. Recent developments include strategic partnerships, the Alexforbes stake sale, and rebranding to Prudential Wealth Advisors, reflecting ongoing business transformation.
PRU presents a mixed outlook with strong fundamentals offset by technical weakness. The company's $3 billion capital rotation plan and focus on core businesses provide growth potential, but investor sentiment remains cautious with 67.57% hold ratings. Key risks include execution of strategic initiatives and interest rate sensitivity, while current valuation below consensus target offers potential upside for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Prudential Financial Inc
Prudential Financial is a large, diversified insurance company offering annuities, life insurance, retirement plan services, and asset management products. While it operates in a number of countries, the vast majority of revenue is generated in the United States and Japan. The company's investment management business, PGIM, contributes approximately 15% of its earnings and has over $1.5 trillion in assets under management. The U.S. businesses are responsible for about 45% of earnings and can be classified into Institutional Retirement Strategies, Individual Retirement Strategies, Group Insurance, Individual Life Insurance, and Assurance IQ. Finally, the international business segment of the company contributes approximately 40% of earnings with a strong market position in Japan.
Read more on PRU →
